Cyclooxygenase-2 plays a critical role in retinal ganglion cell death after transient ischemia: Real-time monitoring of RGC survival using Thy-1-EGFP transgenic mice

Neuroscience Research

Volumn 65, Issue 4, 2009, Pages 319-325

  Sakai, Yasuhiro ^a,b   Tanaka, Takayuki ^a,b   Seki, Masaaki ^a   Okuyama, Shinya ^a,b   Fukuchi, Takeo ^a   Yamagata, Kanato ^c   Takei, Nobuyuki ^b   Nawa, Hiroyuki ^b   Abe, Haruki ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

^b NIIGATA UNIVERSITY   (Japan)

^c TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

Author keywords

Cell death; COX 2; Knockout mouse; Retina; Retinal ganglion cell; Thy 1 EGFP; Transgenic mouse

Indexed keywords

CELECOXIB; COMPLEMENTARY DNA; CYCLOOXYGENASE 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL DEATH; CELL SURVIVAL; DEGENERATIVE DISEASE; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OPTIC NERVE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION INJURY; RETINA; RETINA GANGLION CELL; TRANSGENIC MOUSE; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; ANTIGENS, THY-1; CELL DEATH; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; GREEN FLUORESCENT PROTEINS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; PYRAZOLES; REPERFUSION INJURY; RETINAL GANGLION CELLS; SULFONAMIDES;

EID: 70350610664     PISSN: 01680102     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neures.2009.08.008     Document Type: Article

References (28)

1. Anderson D.R., and Davis E.B. Sensitivities of ocular tissues to acute pressure-induced ischemia. Arch. Ophthalmol. 93 (1975) 267-274
2. Ayalasomayajula S.P., and Kompella U.B. Retinal delivery of celecoxib is several-fold higher following subconjunctival administration compared to systemic administration. Pharm. Res. 21 (2004) 1797-1804
3. Buchi E.R. Cell death in the rat retina after a pressure-induced ischemia-reperfusion insult: an electron microscopic study. I. Ganglion cell layer and inner nuclear layer. Exp. Eye Res. 55 (1992) 605-613
4. Dinchuk J.E., Car B.D., Focht R.J., Johnston J.J., Jaffee B.D., Covoington M.B., Contel N.R., Eng V.M., Collins R.J., Czerniak P.M., et al. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase. Nature 378 (1995) 406-409
5. Feng G., Mellor R.H., Bernstein M., Keller-Peck C., Nguyen Q.T., Wallace M., Nerbonne J.M., Lichtman J.W., and Sanes J.R. Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP. Neuron 280 (2000) 41-51
6. Goldblum D., and Mittag T. Prospects for relevant glaucoma models with retinal ganglion cell damage in the rodent eye. Vis. Res. 42 (2002) 471-478
7. Hamada T., Tsuchihashi S., Avanesyan A., Duarte S., Moore C., Busuttil R.W., and Coito A.J. Cyclooxygenase-2 deficiency enhances Th2 immune responses and impairs neutrophil recruitment in hepatic ischemia/reperfusion injury. J. Immunol. 180 (2008) 1843-1853
8. Higashide T., Kawaguchi I., Ohkubo S., Takeda H., and Sugiyama K. In vivo imaging and counting of rat retinal ganglion cells using a scanning laser ophthalmoscope. Invest. Ophthalmol. Vis. Sci. 47 (2006) 2943-2950
9. Hinz B., and Brune K. Cyclooxygenase-2-10 years later. J. Pharmacol. Exp. Ther. 300 (2002) 367-375
10. Iadecola C., Forster C., Nogawa S., Clark H.B., and Ross M.E. Cyclooxygenase-2 immunoreactivity in the human brain following cerebral ischemia. Acta Neuropathol. (Berl.) 98 (1999) 9-14
11. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S., and Ross M.E. Reduced susceptibility to ischemic brain injury and N-methyl-d-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 1294-1299
12. Imai C., Sugai T., Iritani S., Niizato K., Nakamura R., Makifuchi T., Kakita A., Takahashi H., and Nawa H. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients. Neurosci. Lett. 305 (2001) 185-188
13. Ju W.K., and Neufeld A.H. Cellular localization of cyclooxygenase-1 and cyclooxygenase-2 in the normal mouse, rat, and human retina. J. Comp. Neurol. 452 (2002) 392-399
14. Ju W.K., Kim K.Y., and Neufeld A.H. Increased activity of cyclooxygenase-2 signals early neurodegenerative events in the rat retina following transient ischemia. Exp. Eye Res. 77 (2003) 137-145
15. Nakayama M., Uchimura K., Zhu R.L., Nagayama T., Rose M.E., Stetler R.A., Isakson P.C., Chen J., and Graham S.H. Cyclooxygenase-2 inhibition prevents delayed death of CA1 hippocampal neurons following global ischemia. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 10954-10959
16. Nogawa S., Zhang F., Ross M.E., and Iadecola C. Cyclo-oxygenase-2 gene expression in neurons contributes to ischemic brain damage. J. Neurosci. 17 (1997) 2746-2755
17. Perry V.H., Morris R.J., and Raisman G. Is Thy-1 expressed only by ganglion cells and their axons in the retina and optic nerve?. J. Neurocytol. 13 (1984) 809-824
18. Sairanen T., Ristimaki A., Karjalainen-Lindsberg M.L., Paetau A., Kaste M., and Lindsberg P.J. Cyclooxygenase-2 is induced globally in infarcted human brain. Ann. Neurol. 43 (1998) 738-747
19. Sandoson T.A., and Felician O. The potential application of cyclo-oxygenase type 2 inhibitors to Alzheimer's disease. Expert Opin. Investig. Drugs 7 (1998) 519-526
20. Sasaki T., Kitagawa K., Yamagata K., Takemiya T., Tanaka S., Omura-Matsuoka E., Sugiura S., Matsumoto M., and Hori M. Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J. Cereb. Blood Flow Metab. 24 (2004) 107-113
21. Seki M., Tanaka T., Nawa H., Usui T., Fukuchi T., Ikeda K., Abe H., and Takei N. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factor for dopaminergic amacrine cells. Diabetes 53 (2004) 2412-2419
22. Stewart W.F., Kawas C., Corrada M., and Metter E.J. Risk of Alzheimer's disease and duration of NSAID use. Neurology 48 (1997) 626-632
23. Strauss K.I., Barbe M.F., Marshall R.M., Raghupathi R., Mehta S., and Narayan R.K. Prolonged cyclooxygenase-2 induction in neurons and glia following traumatic brain injury in the rat. J. Neurotrauma 17 (2000) 695-711
24. Takahashi K., Saishin Y., Saishin Y., Mori K., Ando A., Yamamoto S., Oshima Y., Nambu H., Melia M.B., Bingaman D.P., and Campochiaro P.A. Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci. 44 (2003) 409-415
25. Takemiya T., Matsumura K., and Yamagata K. Roles of prostaglandin synthesis in excitotoxic brain diseases. Neurochem. Int. 51 (2007) 112-120
26. Teismann P., Tieu K., Choi D.K., Wu D.C., Naini A., Hunot S., Vila M., Jackson-Lewis V., and Przedborski S. Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc. Natl. Acad. Sci. U.S.A. 100 (2003) 5473-5478
27. Weber A., Casini A., Heine A., Kuhn D., Supuran C.T., Scozzafava A., and Klebe G. Unexpected nanomolar inhibition of carbonic anhydrase by COX-2-selective celecoxib: new pharmacological opportunities due to related binding site recognition. J. Med. Chem. 47 (2004) 550-557
28. Xiang Z., Ho L., Valdellon J., Borchelt D., Kelley K., Spielman L., Aisen P.S., and Pasinetti G.M. Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology. Neurobiol. Aging 23 (2002) 327-334